Papers/PMID:38213188
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.
Nutrition reviews2025The record
2 findings drawn from this paper, on 1 compound across 2 endpoints, 1 of them null.
What it reported
How to read these marksWhat moved
1 finding
curcumin — decreases alanine aminotransferase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×2“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease
What did not
1 finding
curcumin — no detected effect on serum alkaline phosphatase
PreliminaryGrade D, Preliminary. Non-human or in vitro only.FindingNull resultreplicated ×3“Curcumin supplementation significantly reduced ALT (weighted mean difference [WMD], -4.10, 95%CI, -7.16 to -1.04) and AST (WMD, -3.27; 95%CI, -5.16 to -1.39), but not ALP (WMD, -0.49; 95%CI, -1.79 to 0.82).”
Quoted verbatim from Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- patients with nonalcoholic fatty liver disease